Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EPS (Basic) (2016 - 2025)

United Therapeutics' EPS (Basic) history spans 17 years, with the latest figure at $8.37 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 24.74% year-over-year to $8.37; the TTM value through Dec 2025 reached $30.13, up 14.0%, while the annual FY2025 figure was $30.13, 13.96% up from the prior year.
  • EPS (Basic) for Q4 2025 was $8.37 at United Therapeutics, up from $7.72 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $8.37 in Q4 2025 and bottomed at $0.63 in Q1 2021.
  • The 5-year median for EPS (Basic) is $5.42 (2022), against an average of $5.21.
  • The largest annual shift saw EPS (Basic) tumbled 79.94% in 2021 before it soared 742.86% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at $2.5 in 2021, then increased by 13.6% to $2.84 in 2022, then skyrocketed by 61.97% to $4.6 in 2023, then skyrocketed by 45.87% to $6.71 in 2024, then rose by 24.74% to $8.37 in 2025.
  • Per Business Quant, the three most recent readings for UTHR's EPS (Basic) are $8.37 (Q4 2025), $7.72 (Q3 2025), and $6.86 (Q2 2025).